Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors

Walser, Marcel; Mayor, Jennifer; Rothenberger, Sylvia

doi:10.3390/v14102242

Cited by 11 publications

(6 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other developments for anti-viral mAbs include bispecific antibodies, single domain antibodies derived from camelids, and other scaffold proteins such as DARPIns and Adnectins that are engineered in the loop regions between more structured regions of the core domain to mimic antibody CDRs [236][237][238][239] . Some of these technologies may be able to target epitopes that are difficult for traditional antibodies to recognize.…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Struble¹,

Rawson²,

Stantchev³

et al. 2023

Preprint

View full text Add to dashboard Cite

Viral diseases represent a major public health concern and an ever-present risk for developing into a future pandemic. Antiviral antibody therapeutics, either alone or in combination with other therapies, have emerged as valuable preventative and treatment options, including during a global emergency. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.

show abstract

Section: Future Directions and Conclusionmentioning

confidence: 99%

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Struble¹,

Rawson²,

Stantchev³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…With a molecular mass of ≈14 to 18 kDa for a standard four‐ or five‐repeat DARPin, these molecules are around one‐tenth the size of antibodies or one‐third the size of Fab fragments. [ 81 ] This smaller size facilitates higher dosing on a molar basis and the potential for improved tissue penetration. Additionally, DARPin molecules can be engineered to modulate local or systemic pharmacokinetics by incorporating extra domains or through PEGylation.…”

Section: Enhancing Chemical Properties Of Ocular Bioactive Moleculesmentioning

confidence: 99%

Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?

Dang,

Shoichet

2023

Advanced Science

View full text Add to dashboard Cite

The complex anatomy and physiological barriers of the eye make delivering ocular therapeutics challenging. Generally, effective drug delivery to the eye is hindered by rapid clearance and limited drug bioavailability. Biomaterial‐based approaches have emerged to enhance drug delivery to ocular tissues and overcome existing limitations. In this review, some of the most promising long‐acting injectables (LAIs) in ocular drug delivery are explored, focusing on novel design strategies to improve therapeutic outcomes. LAIs are designed to enable sustained therapeutic effects, thereby extending local drug residence time and facilitating controlled and targeted drug delivery. Moreover, LAIs can be engineered to enhance drug targeting and penetration across ocular physiological barriers.

show abstract

“…In addition to SARS-CoV-2, Nbs targeting viral glycoproteins have also been developed for other viruses such as Monkeypox virus [33] , and Ebola virus [34] . These Nbs have shown potent antiviral activity in vitro and in animal models, highlighting their potential as therapeutics against viral infections.…”

Section: Therapeutic Approaches Of Nbsmentioning

confidence: 99%